Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00028951
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : July 9, 2013
National Cancer Institute (NCI)
Information provided by:
GOG Foundation

Brief Summary:

RATIONALE: Fibrin sealant may decrease lymphedema following surgery to remove lymph nodes in the groin by helping to seal the lymphatic vessels. It is not yet known if fibrin sealant is effective in decreasing lymphedema following surgery to remove lymph nodes.

PURPOSE: Randomized phase III trial to determine the effectiveness of fibrin sealant in reducing lymphedema following surgical removal of lymph nodes in patients who have cancer of the vulva.

Condition or disease Intervention/treatment Phase
Lymphedema Perioperative/Postoperative Complications Vulvar Cancer Drug: fibrin sealant Procedure: surgical wound closure Phase 3

Detailed Description:


  • Compare the incidence of lymphedema of the lower extremity after lymph node dissection in patients with vulvar malignancies treated with fibrin sealant vs standard care.
  • Compare the frequency of surgical complications in patients treated with fibrin sealant vs standard care.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: After radical vulvectomy or hemivulvectomy and lymphadenectomy, patients receive fibrin sealant to surgical site.
  • Arm II: After surgery, patients receive standard care for closure of surgical site.

Lymphedema is assessed at time of drain removal, at week 6, and then at months 3 and 6.

Patients are followed at week 6 and at months 3 and 6.

PROJECTED ACCRUAL: A total of 120-130 patients (60-65 per treatment arm) will be accrued for this study within 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Primary Purpose: Supportive Care
Official Title: A Phase III Clinical Trial Use of TISSEEL VH Fibrin Sealant to Reduce Lymphedema Incidence After Inguinal Lymph Node Dissection Performed in the Management of Vulvar Malignancies
Study Start Date : January 2003
Actual Primary Completion Date : December 2005

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Incidence of lymphedema of the lower extremity at 1 week, 6 weeks, 3 months, and 6 months postoperatively

Secondary Outcome Measures :
  1. Frequency of surgical complications at 1 week, 6 weeks, 3 months, and 6 months postoperatively

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Diagnosis of vulvar malignancy

    • Stage I-IVB
  • Planned radical vulvectomy or hemivulvectomy AND
  • Ipsilateral or bilateral inguinal lymphadenectomy
  • Presence of groin node metastases is allowed
  • No primary or secondary lymphedema of the lower extremities



  • Over 18

Performance status:

  • GOG 0-3

Life expectancy:

  • Not specified


  • Platelet count at least 100,000/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • No bleeding disorder


  • Bilirubin no greater than 1.5 times normal
  • SGOT no greater than 3 times normal
  • Albumin at least 3.0 g/dL


  • Creatinine no greater than 2.0 mg/dL


  • No prior lower extremity deep vein thrombosis


  • No known sensitivity or anaphylaxis to bovine-derived products
  • No known prior exposure to fibrin tissue adhesive
  • No other malignancy within the past 5 years except nonmelanoma skin cancer
  • No nonhealing ulcer or chronic infection of the lower extremity, including superficial phlebitis
  • No prior fracture of any portion of either leg
  • Preoperative circumferential measurements of legs must differ by less than 3 cm
  • Not pregnant or nursing
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • No prior chemotherapy for a prior malignancy
  • Concurrent adjuvant chemotherapy allowed

Endocrine therapy:

  • Not specified


  • No prior radiotherapy for a prior malignancy
  • No prior radiotherapy to pelvis, abdomen, inguinal area, or lower extremity


  • See Disease Characteristics
  • No prior inguinal surgery
  • No prior surgery to veins or arteries of either leg
  • No other concurrent elective surgery during same operative event as inguinal lymphadenectomy


  • At least 30 days since prior investigational products or devices
  • At least 7 days since prior anticoagulants
  • Concurrent enrollment on GOG-0173 or other adjuvant treatment protocols is allowed
  • No other concurrent investigational products or devices

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00028951

Show Show 49 study locations
Sponsors and Collaborators
Gynecologic Oncology Group
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Jay W. Carlson, DO Gynecologic Oncology of West Michigan
Publications of Results:
Carlson J, Kauderer J, Walker J, et al.: Phase III trial of Tisseel to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. [Abstract] Society of Gynecologic Oncologists, 2007 Annual Meeting on Women's Cancer, March 3-7, 2007, San Diego, CA. A-228, 2007.

Layout table for additonal information Identifier: NCT00028951    
Other Study ID Numbers: CDR0000069149
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: July 9, 2013
Last Verified: December 2005
Keywords provided by GOG Foundation:
perioperative/postoperative complications
stage I vulvar cancer
stage II vulvar cancer
stage III vulvar cancer
stage IVB vulvar cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Vulvar Neoplasms
Postoperative Complications
Lymphatic Diseases
Pathologic Processes
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Vulvar Diseases
Fibrin Tissue Adhesive